相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An inhibitor of Janus kinase 2 prevents polycythemia in mice
Anjili Mathur et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Pyridone 6, A Pan-Janus-Activated Kinase Inhibitor, Suppresses Osteoclast Formation and Bone Resorption through Down-Regulation of Receptor Activator of Nuclear Factor-kappa B (NF-kappa B) Ligand (RANKL)-Induced c-Fos and Nuclear Factor of Activated T Cells (NFAT) c1 Expression
Han Bok Kwak et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2009)
2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2
Mark W. Ledeboer et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors
Stephanos Ioannidis et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Fragment-based discovery of JAK-2 inhibitors
Stephen Antonysamy et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening
Robert Kiss et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Novel strategies for patients with chronic myeloproliferative disorders
Giovanni Barosi et al.
CURRENT OPINION IN HEMATOLOGY (2009)
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms
Ehab Atallah et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole
Tiansheng Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
A. Pardanani et al.
LEUKEMIA (2009)
Kinase drug discovery approaches in chronic myeloproliferative disorders
C. Kumar et al.
ONCOGENE (2009)
Jak2 Inhibitors: Rationale and Role as Therapeutic Agents in Hematologic Malignancies
Jacqueline Sayyah et al.
CURRENT ONCOLOGY REPORTS (2009)
JAK2 Inhibitors: A Reality? A Hope?
Effrosyni Apostolidou et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Selective inhibition of JAK2-Driven erythroid differentiation of polycythemia vera progenitors
Ifat Geron et al.
CANCER CELL (2008)
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Gerlinde Werning et al.
CANCER CELL (2008)
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
Srdan Verstovsek et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic targeting of Janus kinases
Marko Pesu et al.
IMMUNOLOGICAL REVIEWS (2008)
Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2
Joseph M. Gozgit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells
Daniel B. Lipka et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Z3, a novel Jak2 tyrosine kinase small-molecule inhibitor that suppresses Jak2-mediated pathologic cell growth
Jacqueline Sayyah et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The JAK kinases: Not just another kinase drug discovery target
Andrew F. Wilks
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2008)
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
Elizabeth O. Hexner et al.
BLOOD (2008)
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
WP1066 disrupts janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells
Alessandra Ferrajoli et al.
CANCER RESEARCH (2007)
8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells
Zhenfeng Duan et al.
MOLECULAR PHARMACOLOGY (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Akihiro Muto et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells
Laura Pedranzini et al.
CANCER RESEARCH (2006)
X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and NIMM patients with clonal hematopoiesis
Ross L. Levine et al.
BLOOD (2006)
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor
IS Lucet et al.
BLOOD (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of Jak2 tyrosine kinase autophophorylation
EM Sandberg et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs
C Luo et al.
DRUG DISCOVERY TODAY (2004)
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo
EA Harrington et al.
NATURE MEDICINE (2004)
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera
V Ugo et al.
EXPERIMENTAL HEMATOLOGY (2004)
Characterization of a peptide inhibitor of janus kinase 2 that mimics suppressor of cytokine signaling 1 function
LO Flowers et al.
JOURNAL OF IMMUNOLOGY (2004)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia
S Faderl et al.
BLOOD (2003)
Photochemical preparation of a pyridone containing tetracycle: A Jak protein kinase inhibitor
JE Thompson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2002)
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations
M Levis et al.
BLOOD (2001)
分享论文
